Table 2 Demographics and CSF MTBR-tau measures of participants in the pathologically confirmed primary tauopathy cohort

n

29

21

5

2

22

18

10

5

112

Autopsy-confirmed

1

21

5

2

22

18

10

3

82

Pure pathology

N/A

14

5

1

14

13

10

1

58

Copathology (n)

N/A

AD (1), AGD (1), HS + vascular (1), MND (4)

N/A

Vascular (1)

AD (5), LBD (2), vascular (1)

AD (3), PSP (1), LBD (1)

N/A

AD (1), HS (1)

23

Clinical syndromes

N/A

ALS + MCI (1), MCI (1), bvFTD (7), bvFTD + ALS (6), CBS (1), DLB (1), nfvPPA (1), nfvPPA + ALS (1), PPS (1), svPPA (1)

bvFTD (3), nfvPPA (2)

bvFTD (2)

CBS (5), nfvPPA (5), PAGF (1), PSP-RS (11)

bvFTD (4), CBS (9), nfvPPA (4), PSP-RS (1)

AD (1), AD + TES (1), EOAD (3), lvPPA (1), PCA (4)

Cognitively normal (2), bvFTD (2), nfvPPA (1)

83

Age at onset, SD

N/A

60 ± 10

59 ± 4

53 ± 11

65 ± 7

60 ± 7

53 ± 4

49 ± 12 (3)

60 ± 9 (81)

Age at CSF sampling, SD

62 ± 13

64 ± 9

64 ± 9

68 ± 1

70 ± 7

64 ± 7

57 ± 5

50 ± 12

64 ± 10

Interval between CSF collection and death, SD

2 (1)

2 ± 2

5 ± 2

0 ± 0

3 ± 2

3 ± 2

4 ± 1

2 ± 1 (3)

3 ± 2 (82)

Duration, SD

N/A

4 ± 4

6 ± 2

15 ± 11

5 ± 3

4 ± 1

5 ± 3

5 ± 5 (3)

5 ± 4 (81)

Sex, M/F

14/15

12/9

3/2

2/0

10/12

8/10

6/4

2/3

57/55

CDR plus NACC FTLD SB score

0.2 ± 0.5 (17)

10.6 ± 5.1 (17)

11.0 ± 2.1 (5)

9.3 ± 3.2 (2)

5.3 ± 3.1 (13)

6.7 ± 3.7 (17)

6.6 ± 2.2 (7)

6.6 ± 6.3 (5)

6.2 ± 5.0 (83)

CSF MTBR-tau₂₇₅/t-tau, SD

0.00657 ± 0.00078

0.00611 ± 0.00115

0.00676 ± 0.00138

0.00759 ± 0.00013

0.00669 ± 0.00091

0.00525 ± 0.00117

0.00472 ± 0.00085

0.00491 ± 0.00207

0.00608 ± 0.00126

CSF MTBR-tau₂₈₂/t-tau, SD

0.01328 ± 0.00167

0.01203 ± 0.00193

0.01256 ± 0.00216

0.01526 ± 0.00054

0.01273 ± 0.00179

0.01007 ± 0.00191

0.00925 ± 0.00161

0.00963 ± 0.00457

0.01190 ± 0.00244